Henlius Wins Chinese Approval For Rituximab RA Indication

Wider Potential Patient Population Allows Firm ‘Differentiated Strategy’

 
• By Dave Wallace

Henlius says it can now pursue a “differentiated strategy” for its HLX01 rituximab biosimilar in China, after winning approval for a key rheumatoid arthritis indication from the NMPA.

China Flag Thumbs Up
China’s NMPA has approved the Rituxan rival’s RA indication • Source: Micha Klootwijk / Alamy Stock Photo

More from Biosimilars

More from Products